clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Lung Diseases D008171 37 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lymphadenitis D008199 8 associated lipids
Lymphangitis D008205 4 associated lipids
Mycetoma D008271 4 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Mastoiditis D008417 2 associated lipids
Metaplasia D008679 7 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Myocardial Infarction D009203 21 associated lipids
Myxoma D009232 1 associated lipids
Nasal Polyps D009298 26 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Nocardia Infections D009617 6 associated lipids
Endophthalmitis D009877 12 associated lipids
Psittacosis D009956 4 associated lipids
Osteomyelitis D010019 10 associated lipids
Otitis Media D010033 12 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Pain D010146 64 associated lipids
Pancreatitis D010195 10 associated lipids
Parkinson Disease D010300 53 associated lipids
Paronychia D010304 3 associated lipids
Parotid Diseases D010305 1 associated lipids
Parotid Neoplasms D010307 2 associated lipids
Parotitis D010309 4 associated lipids
Peptic Ulcer D010437 19 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Periodontal Abscess D010508 2 associated lipids
Periodontal Pocket D010514 9 associated lipids
Periodontitis D010518 22 associated lipids
Pleural Diseases D010995 4 associated lipids
Pleuropneumonia D011001 3 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Proteinuria D011507 30 associated lipids
Prurigo D011536 4 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Pseudomyxoma Peritonei D011553 1 associated lipids
Psoriasis D011565 47 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Pyelonephritis D011704 5 associated lipids
Radiation Injuries D011832 14 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Rickettsia Infections D012282 5 associated lipids
Rodent Diseases D012376 4 associated lipids
Rosacea D012393 13 associated lipids
Scrub Typhus D012612 3 associated lipids
Serositis D012700 1 associated lipids
Shock, Septic D012772 11 associated lipids
Sinusitis D012852 9 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Skin Neoplasms D012878 12 associated lipids
Skin Ulcer D012883 6 associated lipids
Splenic Diseases D013158 5 associated lipids
Sporotrichosis D013174 3 associated lipids
Stomach Diseases D013272 7 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Synovitis D013585 15 associated lipids
Syphilis D013587 6 associated lipids
Tenosynovitis D013717 3 associated lipids
Tooth Discoloration D014075 7 associated lipids
Tuberculosis D014376 20 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Typhoid Fever D014435 2 associated lipids
Ureteral Diseases D014515 3 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Urethritis D014526 9 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Urination Disorders D014555 9 associated lipids
Urticaria D014581 13 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Whooping Cough D014917 6 associated lipids
Wound Infection D014946 12 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Discitis D015299 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Eye Infections D015817 1 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Bacteremia D016470 9 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Empyema, Pleural D016724 2 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Vakil N Helicobacter pylori treatment: is sequential or quadruple therapy the answer? 2008 Rev Gastroenterol Disord pmid:18641590
Carabias ML et al. [Are the antimicrobials used in community-acquired respiratory infection useful for preventing transmission of meningococcal disease? In vitro study]. 2001 Rev Esp Quimioter pmid:11704772
Gordillo RM et al. [Susceptibility of Streptococcus pyogenes isolates from pharyngeal exudates in Cordoba (Spain)]. 2003 Rev Esp Quimioter pmid:12750758
Cantón E et al. [In vitro susceptibility to antibiotics and the most common Streptococcus pneumoniae serotypes: a multicenter study]. 2005 Rev Esp Quimioter pmid:15915232
Agudo S et al. Rapid detection of clarithromycin resistant Helicobacter pylori strains in Spanish patients by polymerase chain reaction-restriction fragment length polymorphism. 2011 Rev Esp Quimioter pmid:21412667
Díaz-Reganon J et al. [Susceptibility of 36 Helicobacter pylori clinical isolates to four first-line antibiotics and virulence factors]. 2006 Rev Esp Quimioter pmid:16688289
Agudo S et al. [High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children]. 2009 Rev Esp Quimioter pmid:19544100
Orellana MA and Gómez-Lus ML [Which is the best empirical treatment in patients with urethritis?]. 2011 Rev Esp Quimioter pmid:21947096
Vega AE et al. [Detection of resistance to clarithromycin in clinical isolates of Helicobacter pylori from children and adults]. 2003 Rev Esp Quimioter pmid:12750757
Ruiz-Aragón J et al. [Susceptibility to antimicrobial agents of rapidly growing mycobacteria]. 2007 Rev Esp Quimioter pmid:18563216
Guirao-Arrabal E et al. Clarithromycin plus linezolid as a sequential therapy for implantable-cardioverter-defibrillator infection caused by coagulase-negative staphylococci. 2016 Rev Esp Quimioter pmid:26888341
Miglietta F et al. A rare case of Saprochaete capitata fungemia in a critical ill patient without hematologic and oncological disorders. 2016 Rev Esp Quimioter pmid:26785226
Gálvez-Múgica MA et al. [Meta-analysis of clarithromycin compared to other antibiotics for the treatment of lower respiratory tract infections]. 2003 Rev Esp Quimioter pmid:14961134
Alarcón T et al. [In vitro activity of clarithromycin and metronidazole against Helicobacter pylori in different incubation atmospheres]. 2002 Rev Esp Quimioter pmid:12587039
Rubio-Terrés C et al. [Pharmacoeconomic analysis of community-acquired pneumonia treatment with telithromycin or clarithromycin]. 2003 Rev Esp Quimioter pmid:14702121
Abad-Santos F et al. [Meta-analysis of clarithromycin compared with other antimicrobial drugs in the treatment of upper respiratory tract infections]. 2003 Rev Esp Quimioter pmid:14702124
Alarcón T et al. [In vitro activity of furazolidone and nitrofurantoin in Helicobacter pylori clinical isolates and study of mutation rate]. 2005 Rev Esp Quimioter pmid:16446791
Abasolo Osinaga E et al. [Dispensation and cost of antimicrobials in Spain (1998-2000)]. 2005 Rev Esp Quimioter pmid:16446789
Orden Martínez B et al. [Haemophilus spp. antimicrobial susceptibility in Health Area 6 in Madrid, Spain (2000-2004)]. 2005 Rev Esp Quimioter pmid:16130040
Garza González E et al. [Helicobacter pylori erradication and its relation to antibiotic resistance and CYP2C19 status]. 2007 Rev Esp Enferm Dig pmid:17417917
de Artaza Varasa T et al. [Effect of Helicobacter pylori eradication on patients with functional dyspepsia]. 2008 Rev Esp Enferm Dig pmid:19025303
Gisbert JP et al. [What is the current role of clarithromycin in the eradication of Helicobacter pylori?]. 1997 Rev Esp Enferm Dig pmid:9221019
Rodrigo Sáez L et al. [The efficacy of using a short course of 6-day duration (OCA-6) in the treatment to eradicate Helicobacter pylori infection. Omeprazole, clarithromycin, amoxicillin]. 1997 Rev Esp Enferm Dig pmid:9115827
Sainz R et al. [Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group]. 1999 Rev Esp Enferm Dig pmid:10601771
Rojas Feria M et al. Resistance of Helicobacter pylori to antimicrobial treatment in a Seville hospital catchment area. 2000 Rev Esp Enferm Dig pmid:11468787
Rodríguez Téllez M et al. Morphometric estimation of acid output in duodenal ulcer associated with Helicobacter pylori infection. 1999 Rev Esp Enferm Dig pmid:10491487
Gisbert JP [Lansoprazole: a review of its role in Helicobacter pylori eradication therapy]. 1999 Rev Esp Enferm Dig pmid:10231305
González Carro P et al. [Efficacy of an ultrashort protocol in the eradication of Helicobacter pylori]. 1998 Rev Esp Enferm Dig pmid:9780793
Boixeda D et al. Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy. factors that influence Helicobacter pylori eradications success. 2003 Rev Esp Enferm Dig pmid:12760710
Gisbert JP et al. Validation of the 13c-urea breath test for the initial diagnosis of helicobacter pylori infection and to confirm eradication after treatment. 2003 Rev Esp Enferm Dig pmid:12760719
Torres-Debat ME et al. Antimicrobial susceptibility of Helicobacter pylori and mechanisms of clarithromycin resistance in strains isolated from patients in Uruguay. 2009 Rev Esp Enferm Dig pmid:20001152
Boixeda de Miquel D [Efficacy of the triple therapy in the eradication of H. pylori in peptic ulcer]. 1997 Rev Esp Enferm Dig pmid:9494374
Pérez Mota A et al. Helicobacter pylori, efficacy of the new triple therapy in six and twelve-day schedules. 1997 Rev Esp Enferm Dig pmid:9494375
Castro-Fernández M et al. Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori. 2009 Rev Esp Enferm Dig pmid:19630462
Fernández Martos R et al. Acute psychotic episode secondary to Helicobacter pylori eradication treatment. 2017 Rev Esp Enferm Dig pmid:28071063
Murcia J et al. [Acute myocardial failure in a young man: Q-fever myocarditis]. 2002 Rev Esp Cardiol pmid:12199986
Vallejo Camazón N et al. [Ventricular tachycardia and long QT associated with clarithromycin administration in a patient with HIV infection]. 2002 Rev Esp Cardiol pmid:12199987
Olmos Martínez JM et al. [Definitive treatment of Helicobacter pylori infection in MALT low degree gastric lymphoma]. 2003 Rev Clin Esp pmid:14622518
Alba D et al. [Clarithromycin in the treatment of cerebral toxoplasmosis associated with HIV infection]. 1993 Rev Clin Esp pmid:8516514
Díaz F et al. [Cat-scratch disease. A report of 4 cases and a review of the literature]. 1997 Rev Clin Esp pmid:9102668
Baena Díez JM et al. [Are 5 days of omeprazole plus 2 antibiotics enough for eradication of H. pylori? Comments on sample size]. 1999 Rev Clin Esp pmid:10432821
Gisbert JP et al. [Omeprazole plus 2 antibiotics for the eradication of H. pylori, are 5 days of treatment sufficient?]. 1998 Rev Clin Esp pmid:9844453
Gisbert JP et al. [Role of pantoprazole in the eradicating treatment of Helicobacter pylori]. 1998 Rev Clin Esp pmid:9844458
Asencio Marchante R and Lissen Otero E [Secondary prevention of opportunistic infections in HIV-infected patients]. 2001 Rev Clin Esp pmid:11345612
Cofré Guerra J [Pertussis chemoprophylaxis: a sterile effort?]. 2006 Rev Chilena Infectol pmid:16462967
Morfín Maciel BM and Castillo Ramos HA [Reactive polyarthritis and painful dermatographism caused by Helicobacter pylori]. 2002 May-Jun Rev Alerg Mex pmid:12190006
Matieli LC et al. Mycobacterium abscessus endophthalmitis: treatment dilemma and review of the literature. 2006 Retina (Philadelphia, Pa.) pmid:16963860
Unal M et al. Ocular toxicity of intravitreal clarithromycin. 1999 Retina (Philadelphia, Pa.) pmid:10546942
Ding FM et al. Low-dose clarithromycin therapy modulates CD4(+) T-cell responses in a mouse model of chronic Pseudomonas aeruginosa lung infection. 2012 Respirology pmid:22404374
Kikuchi E et al. Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid. 2008 Respirology pmid:18339019